Person who experienced the adverse event (patient)
Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125824491 | 12582449 | 1 | I | 0 | 20160721 | 20160721 | DIR | 0.00 | M | N | 210.00000 | LBS | 20160719 | Y | OT | US |
Drug(s) used by person
Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
125824491 | 12582449 | 1 | PS | GLEEVEC | IMATINIB MESYLATE | 1 | Oral | 400 MG 1 TAB DAILY PO | D | D | F0031 | 20180831 | 0 | 400 | MG | COATED TABLET | QD |
Indications of drugs used
Event ID | CASEID | INDI DRUG SEQ | INDI PT |
---|---|---|---|
125824491 | 12582449 | 1 | Chronic myeloid leukaemia |
125824491 | 12582449 | 1 | Laboratory test abnormal |
125824491 | 12582449 | 1 | Tyrosine kinase mutation assay |
Outcome of event
no results found |
Reactions reported
Event ID | CASEID | DRUG REC ACT | PT |
---|---|---|---|
125824491 | 12582449 | Dizziness | |
125824491 | 12582449 | Haemoglobin decreased |
Reporting Sources (this data is often not reported and may therefore be missing here)
Event ID | CASEID | RPSR COD |
---|---|---|
125824491 | 12582449 | HP |
Therapies reported
Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
---|---|---|---|---|---|---|
125824491 | 12582449 | 1 | 20130417 | 0 |